NovoCure
NVCR
218 hedge funds and large institutions have $1.57B invested in NovoCure in 2026 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 90 increasing their positions, 62 reducing their positions, and 35 closing their positions.
410% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $3.04M
78% more capital inflows, than outflows
Capital inflows: $186M | Capital outflows: $104M
45% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 62
2.58% more ownership
Funds ownership: 86.89% → 89.47% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 35
2% less funds holding
Funds holding: 223 → 218 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EF
Empowered Funds
Havertown,
Pennsylvania
|
+$17.5M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$12.5M |
| 3 |
JP Morgan Chase
New York
|
+$11.2M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$9.97M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
-$18.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$10.1M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$9.15M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$8.76M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.45M |
NVCR Hedge Fund Activity: Q2 2026 in Review
218 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2026, worth a combined $1.57B — up 46% from $1.08B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of NVCR and 33 opened new positions — a net loss of 2 holders — while 62 trimmed existing stakes and 90 added.
The largest buyer was Empowered Funds, opening a new position worth an estimated $17.5M. The largest seller was SG Americas Securities, cutting an estimated $18.3M.
- 218 institutional investors held NovoCure (NVCR) as of Q2 2026, down from 223 in Q1 2026.
- Funds reported $1.57B of NovoCure stock for Q2 2026, up 46% quarter-over-quarter.
- 33 funds opened new NovoCure positions in Q2 2026 and 35 closed out, a net change of -2 holders.
- The largest NovoCure buyer in Q2 2026 was Empowered Funds, an estimated $17.5M added.
- The largest NovoCure seller in Q2 2026 was SG Americas Securities, an estimated $18.3M sold.
Based on aggregated 13F filings for Q2 2026.